SCHEMBL11287166

SCHEMBL11287166

Cc1ccc2c(ccc3ccc(C)nc32)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.61
RAB9A P51151 1/20 0.61
CCR5 P51681 1/20 0.61
CYP1A2 P05177 4/20 0.48
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.45
METAP2 P50579 1/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
CASP6 P55212 1/20 0.45
OPRK1 P41145 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM1A O60341 1/20 0.40
MAPT P10636 1/20 0.40
PARP1 P09874 1/20 0.39
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8571925 0.83 ALDH1A1 (0.53) CCR1RAB9ACCR5CYP1A2ALDH1A1
SCHEMBL7913564 0.81 LMNA (0.65) CCR1RAB9ACCR5CYP1A2ALDH1A1
SCHEMBL18704721 0.78 MAPT (0.47) CCR1RAB9ACCR5CYP1A2ALDH1A1
SCHEMBL874271 0.78 LMNA (0.67) CCR1RAB9ACCR5CYP1A2ALDH1A1
Neocuproine SCHEMBL29639703 0.77 CCR1 (1.00) CCR1RAB9ACCR5CYP1A2LMNA
Neocuproine SCHEMBL11672280 0.77 CCR1 (1.00) CCR1RAB9ACCR5CYP1A2LMNA
Neocuproine SCHEMBL124563 0.77 CCR1 (1.00) CCR1RAB9ACCR5CYP1A2LMNA
Neocuproine SCHEMBL29367091 0.77 CCR1 (1.00) CCR1RAB9ACCR5CYP1A2LMNA
SCHEMBL17051638 0.75 CCR1 (0.60) CCR1RAB9ACCR5CYP1A2ALDH1A1
SCHEMBL6267429 0.75 CCR1 (0.63) CCR1RAB9ACCR5CYP1A2METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10333017-B2 Hole blocking, electron transporting and window layer for optimized CuIn(1−x)Ga(x)Se2 solar cells BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2019-06-25 US claimed
US-20170110616-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED Culn (1-x)Ga(x)Se2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2017-04-20 US claimed
WO-2015143371-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED CUIN(1-X)GA(X)SE2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2015-09-24 WO claimed
US-10333017-B2 Hole blocking, electron transporting and window layer for optimized CuIn(1−x)Ga(x)Se2 solar cells BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2019-06-25 US disclosed
US-10333017-B2 Hole blocking, electron transporting and window layer for optimized CuIn(1−x)Ga(x)Se2 solar cells BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2019-06-25 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20170110616-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED Culn (1-x)Ga(x)Se2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2017-04-20 US disclosed
US-20170110616-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED Culn (1-x)Ga(x)Se2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2017-04-20 US disclosed
US-20170110616-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED Culn (1-x)Ga(x)Se2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2017-04-20 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2015143371-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED CUIN(1-X)GA(X)SE2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2015-09-24 WO disclosed
WO-2015143371-A1 HOLE BLOCKING, ELECTRON TRANSPORTING AND WINDOW LAYER FOR OPTIMIZED CUIN(1-X)GA(X)SE2 SOLAR CELLS BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2015-09-24 WO disclosed
EP-0014929-B1 DIAGNOSTIC MEANS, PROCESS FOR ITS PREPARATION AND ITS USE IN DETERMINING LEUCOCYTES IN BODY FLUIDS Roche Diagnostics GmbH (DE) 1982-01-06 EP disclosed
US-4299917-A IMPREGNATION OF AN ABSORBENT CARRIER WITH A SULPHONPHTHALEIN ESTER AND AN ACTIVATOR BOEHRINGER MANNEHEIM GMBH (DE) 1981-11-10 US disclosed
EP-0014929-A1 Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids Roche Diagnostics GmbH (DE) 1980-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 CCR1 4739/4885RAB9A 2520/4885CCR5 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.